DIANT

DIANT Pharma Inc. is a biopharmaceutical solutions company that specializes in continuous manufacturing technology for nanoparticles and lipid nanoparticles (LNPs). Founded in 2019, the company developed the proprietary DIANT Jet technology, a system designed to replace traditional batch processing with an integrated, closed-loop, and automated manufacturing process. This technology enables precise, inline control over particle size and characteristics while facilitating scalable production from research and development phases through to commercial manufacturing. By consolidating multiple unit operations into a single step, the platform is engineered to improve product quality, increase efficiency, and reduce cGMP manufacturing risks for nucleic acid-based therapies and other advanced treatments.

These solutions are critical for biopharmaceutical partners, CDMOs, and innovators seeking to accelerate time-to-market and improve the reliability of nanoparticle-based medicines. The company’s technology has been recognized for its potential to de-risk development, with the U.S. Food and Drug Administration acquiring a DIANT system for internal research into advanced manufacturing processes. Beyond equipment, DIANT provides extensive R&D, consulting, and formulation services, offering turnkey solutions that help clients overcome the limitations of older, batch-based manufacturing methods across pharmaceutical, nutraceutical, and cosmetic applications.